Потенційні впливи коронавірусів на серцево-судинну систему в умовах пандемії COVID-19

Л.О. Ткаченко, О.А. Єпанчінцева, Б.М. Тодуров

Література  

1. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016;36 (1):78–80. doi: 10.5144/0256-4947.2016.78
2. Alon D, Stein GY, Korenfeld R. Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One. 2013;23;8 (8):e72476. doi: 10.1371/journal.pone.0072476 eCollection 2013.
3. Arentz M, Yim E, Klaff L. et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;19. doi: 10.1001/jama.2020.4326 [Epub ahead of print].
4. ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak. ASEcho.org
5. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect. Dis. 2016;49:129–133. doi: 10.1016/j.ijid.2016.06.015 Epub 2016 Jun 21.
6. Barnes M, Heywood AE, Mahimbo A. et al. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015;101 (21):1738–1747. doi: 10.1136/ heartjnl-2015-307691
7. Brigham and Women’s Hospital COVID-19 Critical Care Clinical Guidelines. http://www. covidprotocols.org/
8. Booth CM, Matukas LM, Tomlinson GA. et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–2809.
9. Chan JWM, Ng CK, Chan YH. et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58:686–689.
10. Chen C, Zhou Y, Wang D.W. ARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;5. doi: 10.1007/s00059-020-04909-z
11. Chen C, Chen C, Yan JT. et al. Analysis of myocardial injury in patients with COVID19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020. 6;48 (0). E008. doi: 10.3760/ cma.j.cn112148-20200225-00123
12. Choi AD, Abbara S, Branch KR. et al. SCCT Guidance for use of cardiac computed tomography amidst the COVID-19 Pandemic. J Cardiovasc Comput Tomogr. 2016;10 (6):435–449. doi: 10.1016/j.jcct.2016.10.002
13. Elkind MS, Harrington RA, Benjamin IJ. Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020. Mar 17. doi: 10.1161/CIRCULATIONAHA.120.046749 [Epub ahead of print].
14. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020. Mar 11. pii:S2213- 2600(20)30116-8. doi: 10.1016/S2213-2600(20)30116-8. [Epub ahead of print].
15. Ferrario CM, Jessup J, Gallagher PE. et al. Effects of renin-angiotensin system blockage on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68:2189–2196.
16. Frederik GPW, Shah PB, Aronow HD. et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC’s Interventional Council and SCAI. JACC. March 2020. doi: 10.1016/j.jacc.2020.03.021.
17. Gao Y. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. J Med Virol. 2020. Mar 17. doi: 10.1002/jmv.25770
18. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy. JAMA. 2020. Published Online 13.03.2020. doi: 10.1001/jama.2020.4031 
19. Guan WJ, Ni ZY, Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Eng J Med. 2020; doi: 10.1056/NEJMoa2002032. [Epub ahead of print].
20. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID19 https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-ahastatement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
21. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020;16. pii: ehaa190. doi: 10.1093/ eurheartj/ehaa190 [Epub ahead of print].
22. Hui H, Zhang Y, Yang X. et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. Medrxiv.org, posted 27.02.2020. doi: 10.1101/20 20.02.24.20027052
23. Hypertension Canada’s Statement on: Hypertension, ACE-Inhibitors and Angiotensin Receptor Blockers and COVID-19. https://hypertension.ca/wp-content/uploads/2020/03/ 2020-30-15-Hypertension-Canada-Statement-on-COVID-19-ACEi-ARB.pdf.
24. Kwong JC, Schwartz KL, Campitelli MA. et al. Acute myocardial infarction after laboratoryconfirmed influenza infection. New Engl. J. Med. 2018;378 (4):345–353. doi: 10.1056/ NEJMoa1702090
25. Lauer SA, Grantz KH, Bi Q. et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann. Intern. Med. 2020. doi: 10.7326/M20-0504 [Epub ahead of print].
26. Li B, Yang J, Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020. doi: 10.1007/s00392-020-01626-9.
27. Liu K, Fang YY, Deng Y. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. (Engl). 2020. 7. doi: 10.1097/ CM9.0000000000000744
28. Mahmud E. The Evolving Pandemic of COVID-19 and Interventional Cardiology. Position of President of Society for Cardiovascular Angiography & Interventions. www.scai.org, 16.03.2020 
29. Marsousi N, Daali Y, Fontana P. et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin. Pharmacokinet. 2018;57 (10):1347–1354. doi: 10.1007/s40262-018-0637-6
30. Mehra MR, Ruschitzka F. COVID-19 Illness and Heart Failure: A Missing Link?. JACC: Heart Failure. 2020: doi: 10.1016/j.jchf.2020.03.004 
31. Nguyen JL, Yang W, Ito K. et al. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016;1 (3):274–281. doi: 10.1001/jamacardio.2016.0433
32. NHSBT/BTS guidance for clinicians on consent for solid organ transplantation in adults and living organ donation in the context of the COVID-19 pandemic. https://bts.org.uk/ wp-content/uploads/2020/03/NHSBT-BTS-consent-guidance-COVID-19-26.3.20.pdf.
33. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID19) in China [Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41 (2):145–151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003 [Epub ahead of print]
34. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/ News/
35. Ruan Q, Yang K, Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020. Mar 3. doi: 10.1007/s00134-020-05991-x
36. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) – United States, February 12 – March 16, 2020. MMWR Morb Mortal. Wkly Rep. 2020;69 (12):343–346. doi: 10.15585/mmwr.mm6912e2
37. Veronese G, Ammirati E, Cipriani M, Frigerio M. Fulminant myocarditis: Characteristics, treatment, and outcomes. Anatol. J. Cardiol. 2018;19 (4):279–286. doi: 10.14744/ AnatolJCardiol.2017.8170 Epub 2018 Mar 13.
38. Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi: 10.1001/ jama.2020.1585 
39. Watkins J. Preventing a covid-19 pandemic. BMJ. 2020; m810. doi: 10.1136/bmj.m810 
40. WHO Coronavirus disease 2019 (COVID-19). Situation Report–41. https://www.who. int/docs/default-source/coronaviruse/situation-reports/20200301-sitrep-41-covid-19. pdf?sfvrsn=6768306d_2
41. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID19). Geneva: WHO; 2020. Available from: https://www.who.int/docs/ default-source/coronaviruse/whochina-joint-mission-on-covid-19-final-report.pdf]
42. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. Published online February 24, 2020. doi: 10.1001/jama.2020.2648 
43. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. Published online 18 March 2020. doi: 10.1093/eurheartj/ehaa231 
44. Xu Z, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. Feb 18. pii:S2213-2600(20)30076-X.
45. Yang J, Zheng Y, Gou X. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Intern. J. Infectious Diseases. 2020. doi: 10.1016/j.ijid.2020.03.017 
46. Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARSCoV2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. 24. pii:S2213-2600(20)30079-5. doi: 10.1016/S2213- 2600(20)30079-5 [Epub ahead of print]
47. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med. 2020. doi: 10.1007/s00134-020-05993-9 
48. Zheng Y, Ma Y, Zhang J. et al. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020. Mar 5. doi: 10.1038/s41569-020-0360-5 [Epub ahead of print]

49. Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3

50. Zhu ZW, Tang JJ, Chai XP. et al. Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(0):E007. doi: 10.3760/cma.j.cn112148-20200218-00093. [Epub ahead of print]

Прогностична роль васкулоендотеліального фактора росту А в пацієнтів, які перенесли гострий інфаркт міокарда

М.П. Копиця, І.М. Кутя, Ю.В. Родіонова, Я.В. Гільова

Література  

1. Оrder of the Ministry of Health of Ukraine N 455. 02.07.2014 (in Ukr).
2. Berezin AE. Predictive Role of Circulating Vascular Endothelial Growth Factor-1 in Patients with Cardiovascular Diseases. J Dis Markers. 2014;1(3):1-6. doi: 10.4172/2165-8048.S11-006
3. Deuse T, Peter C, Fedak PW, Doyle T, Reichenspurner H, Zimmermann WH, Eschenhagen T, Stein W, Wu JC, Robbins RC and Schrepfer S. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation. 2009;120(11):S247-54. doi: 10.1161/CIRCULATIONAHA.108.843680
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676. doi: 10.1038/nm0603-669
5. Garcia R, Bouleti C, Sirol M, Logeart D, Monnot C, Ardidie-Robouant C. VEGF-A plasma levels are associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2019;291:19-24. doi: 10.1016/j.ijcard.2019.02.067
6. Hagikura K, Fukuda N, Yokoyama S, Yuxin L, Kusumi Y, Matsumoto T, Ikeda Y, Kunimoto S, Takayama T, Jumabay M, Mitsumata M, Saito S, Hirayama A, Mugishima H. Low invasive angiogenic therapy for myocardial infarction by retrograde transplantation of mononuclear cells expressing the VEGF gene. Int J Cardiol. 2010;142:56-64. doi: 10.1016/j.ijcard.2008.12.108 Epub 2009 Jan 24.
7. Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM and Simoons ML;and on Behalf of the CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators:Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003;107:524-530. doi: 10.1161/01.CIR.0000048183.37648.1A
8. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549-80. doi: 10.1124/pr.56.4.3
9. Hojo Y, Ikeda U, Zhu Y, Okada M, Ueno S, Arakawa H, Fujikawa H, Katsuki T and Shimada K. Expression of vascular endothelial growth factor in patients with acute myocardial infarct. J Am Coll Cardiol. 2000;35:968-973. doi: 10.1016/s0735-1097(99)00632-4
10. Kranz A, Rau C, Kochs M, Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction:Evidence for its origin and functional significance. J Mol Cell Cardiol. 2000;32:65-72. doi: 10.1006/jmcc.1999.1062
11. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2 and vascular endothelial growth factor levels in acute coronary syndromes. Circulation. 2004;110:2355-2360. doi: 10.1161/01.CIR.0000138112.90641.7F
12. Matsudaira K, Maeda K, Okumura N, Yoshikawa D, Morita Y, Mitsuhashi H, Ishii H, Kondo T and Murohara T;Nagoya Acute Myocardial Infarction Study (NAMIS) Group:Impact of low levels of vascular endothelial growth factor after myocardial infarction on 6-month clinical outcome:Results from the Nagoya Acute Myocardial Infarction Study. Circ J. 2012;76:1509-151. doi: 10.1253/circj.CJ-11-1127
13. Niu J, Han X, Qi H. :Jiamin Niu, Xia Han, Huaxin Qi, Jie Yin, Zhiqiang Zhang. Correlation between vascular endothelial growth factor and long-term prognosis in patients with acute myocardial infarction. Experimental and Therapeutic Medicine. 2016;12(1):475-479. doi: 10.3892/etm.2016.3286
14. Ogawa H, Suefuji H, Soejima H, Nishiyama K, Misumi K, Takazoe K, Miyamoto S, Kajiwara I, Sumida H, Sakamoto T, et al. Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology. 2000;93:93-99. doi: 10.1159/000007008
15. Pannitteri G, Petrucci E, Testa U. Coordinate release of angiogenic growth factors after acute myocardial infarction:evidence of a two-wave production. J Cardiovasc Med. 2006;7(12):872-879. doi: 10.2459/01.JCM.0000253831.61974.b9
16. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891-975. doi: 10.1093/eurheartj/ehw128
17. Ramos K, Napoleao P, Selas M, Freixo C, Viegas Crespo AM, Carmo MM, Ferreira RC, and Pinheiro T. Prognostic value of VEGF in patients submitted to percutaneous coronary intervention. Hindawi Publishing Corporation. 2014. Article ID:135357, 7 pages. doi: 10.1155/2014/135357
18. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y. Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103:2776-2779. doi: 10.1161/hc2301.092122
19. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K and Fukuda N. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology. 2000;93:168-174. doi: 10.1159/000007022
20. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Serum hepatocyte growth factor predicts ventricular remodeling following myocardial infarction. Circ J. 2002;66:1003-1007. doi: 10.1253/circj.66.1003
21. Taimeh Z, Loughran J, Birks EJ, Bolli R. Vascular endothelial growth factor in heart failure. Nat Rev Cardiol. 2013;10(9):519-530. doi: 10.1038/nrcardio.2013.94 Epub 2013 Jul 16.
22. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD;ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-269. doi: 10.1093/eurheartj/ehy462
23. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I;ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339
24. Ye L, Zhang W, Su LP, Haider HK, Poh KK, Galupo MJ, Songco G, Ge RW, Tan HC and Sim EK:Nanoparticle based delivery of hypoxia-regulated VEGF transgene system combined with myoblast engraftment for myocardial repair. Biomaterials. 2011;32:2424-2431. doi: 10.1016/j.biomaterials.2010.12.008
25. Yin R, Feng J, Chen D and Wu H. Serum levels of vascular endothelial growth factor in patients with anginapectoris and acute myocardial infarct. Chin Med Sci J. 2000;15:205-209. PMID:12906138
26. Zhao T, Zhao W, Chen Y, Ahokas RA, Sun Y. Vascular endothelial growth factor (VEGF)-A:role on cardiac angiogenesis following myocardial infarction. Microvasc Research. 2010;80(2):188-194. doi: 10.1016/j.mvr.2010.03.014

Рецидиви аритмії тa пізні серцево-судинні ускладнення в пацієнтів із персистентною фібриляцією передсердь після відновлення синусового ритму

У.П. Черняга-Ройко, Н.С. Павлик, М.С. Сороківський, А.В. Акер, О.Й. Жарінов

Література  

1. Оrder of the Ministry of Health of Ukraine 15.06.2016 N 597(in Ukr).
2. Alcaraz R, Hornero F, Rieta J.J. et al. Noninvasive time and frequency predictors of long-standing atrial fibrillation early recurrence after electrical cardioversion. Pacing Clin Electrophysiol.– 2011;34(10):1241–1250. doi: 10.1111/j.1540-8159.2011.03125.x
3. Alzahrani T, McCaffrey J, Mercader M. et al. Rate versus rhythm control in patients with normal to mild left atrial enlargement: insights from the AFFIRM Trial. J Atr Fibrillation.– 2018;11(3):2067. doi: 10.4022/jafib.2067
4. Connolly S.J, Crijns H.J, Torp-Pedersen C. et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation.– 2009;120(13):1174–1180. doi: 10.1161/CIRCULATIONAHA.109.875252
5. Corley SD, Epstein AE, DiMarco JP. et al. Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM). Study Circulation. 2004;109:1509–1513. doi: 10.1161/01.CIR.0000121736.16643.11
6. Forkmann M, Schwab C, Edler D. at al. Characteristics of early recurrences detected by continuous cardiac monitoring influencing the long-term outcome after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2019;30(10). Р. 1886–1893. doi: 10.1111/jce.14109
7. Kelly JP, DeVore AD, Wu J. et al. Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from get with the guidelines-heart failure. J Am Heart Assoc.– 2019;8(24):e011560. doi: 10.1161/JAHA.118.011560
8. Kirchhof P, Benussi S, Kotecha D. et al. ESC Guidelines for the management of atrial fibrillation developed in collabo¬ration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi: 10.1093/ejcts/ezw313
9. Miura K, Ikemura N, Kimura T. et al. Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation. Am Heart J. 2020;21 (222):83–92. doi: 10.1016/j.ahj.2020.01.011
10. Müller P, Schiedat F, Dietrich JW. et al. Reverse atrial remodeling in patients who maintain sinus rhythm after electrical cardioversion: evidence derived from the measurement of total atrial conduction time assessed by PA-TDI interval. J Echocardiogr. – 2014;12(4):142–150. doi: 10.1007/s12574-014-0227-z
11. Rienstra M, Vermond RA, Crijns HJ. et al. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm. 2014;11(6):939–945. doi: 10.1016/j.hrthm.2014.03.016
12. Roy D. Rationale for the Atrial Fibrillation and Congestive Heart Failure(AF-CHF) trial. Card Electrophysiol Rev.– 2003;7(3):208–210. doi: 10.1023/B:CEPR.0000012383.63580.c8
13. Shah R, Manesh M. et al. Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. Ther Adv Cardiovasc Dis. 2017;11(3):105–120. doi: 10.1177/1753944716663156
14. Vamos M, Calkins H, Kowey PR. et al. Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study. Clin Cardiol 2020;43(3):291–297. doi: 10.1002/clc.23309
15. Weijs B, Limantoro I, Delhaas T. et al. Cardioversion of persistent atrial fibrillation is associated with a 24-hour relapse gap: Observations from prolonged postcardioversion rhythm monitoring. Clin Cardiol. – 2018;41(3):366–371. doi: 10.1002/clc.22877
16. Xiong N, Shen J, Wu B.J. et al. Factors influencing cognitive function in patients with atrial fibrillation: a cross-sectional clinical study. Int Med Res. 2019;47(12):6041–6052. doi: 10.1177/0300060519882556

Перший досвід застосування в Україні безелектродної системи кардіостимуляції

О.М. Грицай, Я.В. Скибчик, Є.В. Житинський, В.О. Куць, О.Й. Жарінов

Література  

1. Afzal MR, Daoud EG, Cunnane R. et al. Techniques for successful early retrieval of the micra transcatheter pacing system: a worldwide experienc. Heart Rhythm. 2018;15(6):841–846. doi: 10.1016/j.hrthm.2018.02.008
2. Al-Mohaisen MA, Chan KL. Prevalence and mechanism of tricuspid regurgitation following implantation of endocardial leads for pacemaker or cardioverter-defibrillator. J Am Soc Echocardiogr. 2012;25:245–252. doi: 10.1016/j.echo.2011.11.020
3. Bhatia N, El-Chami M. Leadless pacemakers: a contemporary review. J Geriatric Cardiology. 2018;15:249–253. doi: 10.11909/j.issn.1671-5411.2018.04.002
4. Buch E, Boyle NG, Belott PH. Pacemaker and defibrillator lead extraction. Circulation. 2011;123:e378–380. doi: 10.1161/CIRCULATIONAHA.110.987354
5. DeSimone CV, Friedman PA, Noheria A. et al. Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale. Circulation. 2013;128:1433–1441. doi: 10.1161/CIRCULATIONAHA.113.003540
6. Duray GZ, Ritter P, El-Chami M. et al. Long-term performance of a transcatheter pacing system: 12-month results from the micra transcatheter pacing study. Heart Rhythm. 2017;14:702–709. doi: 10.1016/j.hrthm.2017.01.035 
7. Epstein AE, DiMarco JP, Ellenbogen KA. et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51(21):e1–e62. doi: 10.1016/j.jacc.2008.02.032
8. Johansen JB, Jørgensen OD, Møller M. et al. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J. 2011;32:991–998. doi: 10.1093/eurheartj/ehq497
9. Kirkfeldt RE, Johansen JB, Nohr EA. et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35:1186–1194. doi: 10.1093/eurheartj/eht511
10. Kirkfeldt RE, Johansen JB, Nohr EA. et al. Risk factors for lead complications in cardiac pacing: a population-based cohort study of 28,860 Danish patients. Heart Rhythm. 2011;8:1622–1628. doi: 10.1016/j.hrthm.2011.04.014
11. Knops RE, Tjong FVY, Neuzil P. et al. Chronic performance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS Trial. J Am Coll Cardiol. 2015;65:1497–1504. doi: 10.1016/j.jacc.2015.02.022
12. Lloyd M, Reynolds D, Sheldon T, et al. Rate adaptive pacing in an intracardiac pacemaker. Heart Rhythm. 2017;14:200–205. doi: 10.1016/j.hrthm.2016.11.016
13. Maytin M, Epstein LM, Henrikson CA. Lead extraction is preferred for lead revisions and system upgrades: when less is more. Circ Arrhythm Electrophysiol. 2010;3:413–424. doi: 10.1161/CIRCEP.110.9541
14. Compton SJ, DiMarco JP, Hackett K. et al. Medtronic. Cardiac Rhythm Disease Management. Product Performance Report. 2013 Second Edition – Issue 68. Available at: wwwp.medtronic.com/productperformance-files/.
15. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009 – a World Society of Arrhythmia’s project. Pacing Clin Electrophysiol. 2011;34:1013–1027. doi: 10.1111/j.1540-8159.2011.03150.x
16. Mondésert B, Dubuc M, Khairy P. et al. Combination of a leadless pacemaker and subcutaneous defibrillator: first in human report. Heart Rhythm Case Rep. 2015;1:469–471. doi: 10.1016/j.hrcr.2015.07.009
17. Niek EG, Beurskens L, Fleur VY. et al. Successful replacement of the longest worldwide in situ Nanostim leadless cardiac pacemaker for a Micra Transcatheter Pacing System. J Interv Cardiac Electrophysiology. 2018;51:161–162. doi: 10.1007/s10840-017-0310-2
18. Okabe T, El-Chami MF, Lloyd MS. et al. Leadless pacemaker implantation and concurrent atrioventricular junction ablation in patients with atrial fibrillation. Pacing Clin Electrophysiol Published Online First: Feb 24, 2018. doi: 10.1111/pace. 13312
19. Piccini JP, Stromberg K, Jackson KP. et al. Long-term outcomes in leadless Micra transcatheter pacemakers with elevated thresholds at implantation: Results from the Micra Transcatheter Pacing System Global Clinical Trial. Heart Rhythm. 2017;14:685–691. doi: 10.1016/j.hrthm.2017.01.026
20. Przybylski A, Derejko P, Kwasniewski W. et al. Bleeding complications after pacemaker or cardioverter-defibrillator implantation in patients receiving dual antiplatelet therapy: Results of a prospective, two-centre registry. Neth Heart J. 2010;18:230–235. doi: 10.1007/BF03091768
21. Reddy VY, Knops RE, Sperzel JS. et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation. 2014;129:1466–1471. doi: 10.1161/CIRCULATIONAHA.113.006987
22. Reddy VY, Exner DV, Cantillon DJ. et al. LEADLESS II. Percutaneous implantation of an entirely intracardiac leadless pacemaker. New Engl J Med. 2015;373:1125–1135. doi: 10.1056/NEJMoa1507192
23. Reynolds D, Duray GZ, Omar R. et al. A leadless intracardiac transcatheter pacing system. New Engl J Med. 2016;374:533–541. doi: 10.1056/NEJMoa1511643
24. Roberts PR, Clementy N, Al Samadi F, Garweg C, Martinez-Sande JL, Iacopino S, Johansen JB, Prat XV, Kowal RC, Klug D, Mont L, Steffel J, Li S, van Osch D, El-Chami MF. A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. Heart Rhythm. 2017;14:1375–1379. doi: 10.1016/j.hrthm.2017.05.017
25. Tjong FVY, Reddy VY. Permanent leadless cardiac pacemaker therapy. A comprehensive review. Circulation. 2017;135:1458–1470. doi: 10.1161/CIRCULATIONAHA.116.025037
26. Tjong FV, Brouwer TF, Kooiman KM. et al. Communicating antitachycardia pacing-enabled leadless pacemaker and subcutaneous implantable defibrillator. J. Am. Coll. Cardiol. 2016;67:1865–1866. doi: 10.1016/j.jacc.2016.02.039
27. Tracy CM, Epstein AE, Darbar D. et al. 2012 ACCF/AHA/ HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2013;61:e6–e755. doi: 10.1016/j.jtcvs.2012.08.032
28. Udo EO, Zuithoff NP, van Hemel NM. et al. Incidence and predictors of shortand long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9:728–735. doi: 10.1016/j.hrthm.2011.12.014
29. Vamos M, Erath JW, Benz AP. et al. Incidence of cardiac perforation with conventional and with leadless pacemaker systems: a systematic review and meta-analysis. J. Cardiovasc. Electrophysiol. 2017;28:336–346. doi: 10.1111/jce.13140
30. Yarlagadda B, Turagam MK, Dar T. et al. Safety and feasibility of leadless pacemaker in patients undergoing atrioventricular node ablation for atrial fibrillation. Heart Rhythm. 2018;15(7):994–1000. doi: 10.1016/j.hrthm.2018.02.025

Асцендо-десцендоаортальне протезування з реімплантацією брахіоцефальних судин при аневризмі дуги та низхідної частини аорти на тлі гіпоплазії дуги та коарктації аорти

Б.М. Тодуров, О.В. Зеленчук, С.М. Судакевич, А.Ю. Шкандала, Н.С. Гноянко

Література  

1. Belov YV, Stepanenko AB, Gens AP, Komarov RN, Chernyavskiy SV, Stogniy NY. Step-by-step surgical treatment of a patient with Ehlers-Danlo syndrome, coarctation of the aorta and aneurysm of the ascending aorta with aortic insufficiency. Cardiology and cardiovascular surgery. 2011;4:83-87 (in Russ.).
2. Lysenko АV, Belov YV, Komarov RN, Stonogin АV. Resection of coarctation of the aorta with exoprosthetic anastomosis and postcoarctation aneurysm of the descending thoracic aorta. Cardiology and cardiovascular surgery. 2015,5:64-72. doi:10.17116/kardio20158569-72 (in Russ.).
3. Barron DJ, Lamb RK, Ogilvie BC. et al. Technique for extra anatomic bypass in complex aortic coarctation. Ann Thorac Surg. 1996;61:241-244. doi: 10.1016/0003-4975(95)00942-6
4. Beckmann E, Jassar AS. Coarctation repair-redo challenges in the adults: what to do? J Vis Surg. 2018;4:76. doi: 10.21037/jovs.2018.04.07
5. Boris JR. Primary-care management of patients with coarctation of the aorta. Cardiol Young. 2016;26(8):1537-1542. doi: 10.1017/S1047951116001748
6. Connolly HM, Schaff HV, Uzi Izhar, Dearani JA, Warnes CA, Orszulak TA. Posterior Pericardial Ascending-to-Descending Aortic Bypass An Alternative Surgical Approach for Complex Coarctation of the Aorta. Circulation. 2001;104[suppl 1]:I-133-I-137. doi: 10.1161/hc37t1.094897
7. Crafoord C, Nylin G. Congenital coarctation of the aorta and its surgical treatment. J Thorac Surg. 1945;14:347–61.
8. Donazzan L, Crepaz R, Stuefer J, Stellin G. Abnormalities of aortic arch share, central aortic flow dynamics, and distensibility predispose to hypertention after successful repair of aortic coarctation. World J Pediatr Congenit Heart Surg. 2014;5(4):546-53. doi:1177/2150135114551028
9. Dotty DB, Dotty JR. Cardiac surgery: operative technique, 2nd ed. Elsevier Saunders, 2012.
10. Edie R, Janani J, Attai L. et al. Bypass grafts for recurrent or complex coarctation of the aorta. Ann Thorac Surg. 1975;20:558 –566. doi:10.1016/S0003-4975(10)64255-5
11. Friedman WF. Congenital heart disease in infancy and childhood. In: Braunwald, ed. Heart disease: a textbook of cardiovascular medicine, 5th edn. Philadelphia, WB Saunders, 1997:877-962.
12. Hanneman K, Newman B, Chan F. Congenital Variants and Anomalies of the AorticArch. Radiographics.2017;37(1):32-51.doi:10.1148/rg.2017160033
13. Grinda J, Mace L, Dervanian P. et al. Bypass graft for complex forms of isthmic aortic coarctation in adults. Ann. Thorac. Surg. 1995;60:1299-1302. doi: 10.1016/0003-4975(95)00557-2
14. Hoffman JI. The challenge in diagnosing coarctation of the aorta. Cardiovasc J. Afr. 2018 Jul/Aug; 2329(4):252-255. doi: 10.5830/CVJA-2017-053
15. Holzer RJ, Chisolm JL, Hili SL, Cheatham JP. Stenting complex aortic arch obstractions. Catheter Cardiovasc Interv.2008;15;71(3):375-82. doi:10.1002/ccd.21357.
16. Folliguet T, Mace L, Dervanian P. et al. Surgical treatment of diffuse supravalvular aortic stenosis. Ann. Thorac. Surg. 1996;61(4):1251–1253. doi: 10.1016/0003-4975(95)01065-3
17. Jacob T, Cobanoglu A, Starr A. Late results of ascending aorta-descending aorta bypass grafts for recurrent coarctation of aorta. J. Thorac. Cardiovasc. Surg. 1988;95(5):782–787. doi: 10.1016/S0022-5223(19)35688-0
18. Maxey TS, Serfontein SJ, Reece TB, Rheuban KS, Kron IL. Transverse arch hypoplasia may predispose patient to aneurysm formation after patch repair of aortic coarctation. Ann. Thorac. Surg. 2003;76(4):1090-3. doi:10.1016/s0003-4975(03)00822-1
19. Mulay A, Ashraf S, Watterson K. Two-stage repair of adult coarctation of the aorta with congenital valvular lesions. Ann. Thorac. Surg. 1997;64(5):1309–1311. doi:10.1016/S0003-4975(97)00814-X
20. Powell W, Adams P, Cooley D. Repair of coarctation of the aorta with intracardiac repair. Tex. Heart Inst. J. 1983;10(4):409-413. PMID:15226976
21. Preventza O, Livesay JJ, Cooley DA, Krajcer Z, Cheong BY, Coselli JS. Coarctation-Associated aneurysms: a localized disease or diffuse aortopathy. Ann. Thorac. Surg. 2013;95(6):1961-1967. doi:10.1016/j.athoracsur.2013.03.062.
22. Pushparajah K, Sadiq M, Brzezinska-Rajszys G, Thomson J, Rosenthal E, Qureshi SA. Endovascular stenting in transverse aortic arch hypoplasia. Catheter. Cardiovasc. Interv. 2013;82(4):E491-9. doi: 10.1002/ccd.24735.
23. Quennelle S, Powell AJ, Geva T, Prakash A. Persistent aortic arch hypoplasia after coarctation treatment is associated with late systemic hypertension. J Amer Heart Association. doi: 10.1161/JAHA.115.001978
24. Said SM, Burkhart HM, Dearani JA, Connolly HM, Schaff HV. Ascending-to-descending aortic bypass:a simple solution to a complex problem. Ann. Thorac. Surg. 2014;97:2041-8. doi:10.1016/j.athoracsur.2014.02.030
25. Sweeney M, Walker W, Duncan J et al. Reoperation for aortic coarctation:techniques, results, and indications for various approaches. Ann Thorac Surg. 1985;40(1):46-49. doi: 10.1016/s0003-4975(10)61168-x
26. Vijayanagar R, Natarajan P, Eckstein P. et al. Aortic valvular insufficiency and postductal aortic coarctation in the adult: combined surgical management through median sternotomy: a new surgical approach. J Thorac Cardiovasc Surg. 1980;79(2):266-268.
27. Warmerdam EG, Krings GJ, Meijs TA, Franken AC, Driesen BW, Sieswerda GT, Meijboom FJ, Doenendans PAF, Molenschot MMC, Voskuil M. Safety and efficacy of stending for aortic arch hypoplasia in patients with coarctation of the aorta. Neth Heart. J. 2020;28:145-152. doi: 10.1007/s12471-019-01353-5
28.Webb G. Treatment of coarctation and late complications in the adult. Semin Thorac Cardiovasc Surg. 2005;17(2):139–42. doi: 10.1053/j.semtcvs.2005.03.001
29.Yetman AT, Starr L, Sanmann J, Wilde M, Murray M, Cramer JW. Clinical and Echocardiographic Prevalence and Detection of Congenital and Acquired Cardiac Abnormalities in Girls and Women with the Turner Syndrome. Am J Cardiol. 2018; Jul 15;122(2):327-330. doi: 10.1016/j.amjcard.2018.03.357

До питання про складність диференціальної діагностики пухлин серця і перикарда

Р.М. Вітовський, В.В. Ісаєнко, Є.В. Аксьонов, І.Г. Яковенко, М.А. Трегубова, О.А. Мазур

Література  

1. Burke A, Tavora F. The 2015 WHO Classification of tumors of the heart and pericardium. J Thoracic Oncology. 2015. doi: 10.1016/j.jtho.2015.11.009
2. Hudzik B, Miszalski-Jamka K, Glowacki J, Lekston A, Gierlotka M, Zembala M, Polonski L, Gasior M. Malignant tumors of the heart. Cancer Epidemiol. 2015;39 (5):665–672. doi: 10.1016/j.canep.2015.07.007
3. Mkalaluh S, Szczechowicz M, Torabi S, Schmack B, Sabashnikov A, Dib B, Karck M, Weymann A. Surgical treatment of cardiac tumors: Insights from an 18-year single-center analysis. Med. Sci Monit. 2017;23:6201–6209. doi: 10.12659/msm.90545
4. Yanagawa B, Mazine A, Chan EY, Barker CM, Gritti M, Reul RM, Ravi V, Ibarra S, Shapira OM, Cusimano RJ, Reardon MJ. Surgery for Tumors of the Heart. Semin Thorac Cardiovasc Surg. 2018. Sep. 8. doi: 10.1053/j.semtcvs.2018.09.001
5. Yin L, He D, Shen H, Ling X, Li W, Xue Q, Wang Z. Surgical treatment of cardiac tumors: a 5-year experience from a single cardiac center. J. Thorac. Dis. 2016;8(5):911–919. doi: 10.21037/jtd.2016.03.87

Чи зберігається місце нітратів у лікуванні серцевої недостатності?

І.В. Шклянка, О.А. Єпанчінцева, О.Й. Жарінов

Література  

1. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. New Engl J Med. 1986;314:1547-1552. doi: 10.1056/NEJM198606123142404
2. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Bruce W Dunkman, Loeb H, Wong M, Bhat G, Goldman S et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl J Med. 1991;325:303-310. doi: 10.1056/NEJM199108013250502
3. Elliot H. Current Issues in Cardiovascular Therapy. Martin Dunitz, Glasgow, UK, 1997.
4. Gupta D, Georgiopoulou VV, Kalogeropoulos AP. et al. Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. JACC: Heart Failure. 2013;1 (Iss. 3):183-191.
5. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41 (3):407-477. doi: 10.1093/eurheartj/ehz425
6. Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease. The task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34 (38):2949-3003.
7. Mullens W, Abrahams Z, Francis GS. et al. Usefulness of isosorbide dinitrate and hydralazine as add on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol. 2009;103:1113-1119.
8. Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1093/eurheartj/ehw128
9. Redfield MM, Anstrom KJ, Levine JA. et al. NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in heart failure with preserved ejection fraction. New Engl J Med. 2015;373 (24):2314-2324.
10. Tsujimoto Tetsuro, Kajio Hiroshi. Use of nitrates and risk of cardiovascular events in patients with heart failure with preserved ejection fraction. Mayo Clinic Proceedings. 2019;94:1125-1127. doi: 10.1016/j.mayocp.2018.11.032
11. Vizzardi E, Bonadei I, Riccardo R. et al. When should we use nitrates in congestive heart failure? Cardiovascular Therapeutics. 2013;31:27-31. doi: 10.1111/j.1755-5922.2012.00311
12. Yancy CW, Jessup M, Bozkurt B. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-e161. doi: 10.1161/CIR.0000000000000509